Autoimmune encephalitis is swelling of the brain caused by the immune system attacking the body in error. It can cause people to become confused, drowsy, exhibit changes in behaviour, and have seizures. It affects around 1 in 100,000 people per year in the UK and because of its rarity and varied symptoms, receiving a diagnosis can be a lengthy process.<\/p>\n
Delays in diagnosis of autoimmune encephalitis, and the lack of specific targeted treatment, have a negative impact on patient\u2019s recovery. Thankfully, there is lots of ongoing work to raise awareness of the disease and research trials, like the Enceph-IG trial, are working to identify better treatment options. The Enceph-IG trial is looking to determine if intravenous immunoglobulin (IVIG) can help improve recovery time.<\/p>\n
Running a trial in a rare disease area is challenging, but even more so these days with the ongoing impact of COVID-19 on research in the NHS. In most other trials, many hospital sites can take part because the condition is much more common. But for rare diseases like autoimmune encephalitis, the pool of hospitals is much smaller due to the requirement of staff to have the appropriate disease-related knowledge to be able to treat the condition. Even though the Enceph-IG trial is working in a rare disease area, we are actually looking for hospitals that may not regularly see patients with autoimmune encephalitis. We have worked hard with doctors and other healthcare staff to make sure the skills and knowledge needed to deliver the trial are those that lots of clinical staff will have.<\/p>\n
Another challenging element of doing research in a rare disease area is that patients with autoimmune encephalitis are few and far between. This means it might be weeks or even months between potential participants presenting at a hospital. This can make it really tricky to identify patients who are suitable for the trial, and it makes it easy to forget all the different trial activities.<\/p>\n
To help solve this problem, we have encouraged sites to raise awareness of the trial by displaying posters and by attending regular meetings at their hospital. Some sites have had great success working with the local lab to set up alerts for when someone requests a test that might mean there is a patient with autoimmune encephalitis. We have also developed short guides to remind everyone of the different activities they need to do.<\/p>\n
We are also doing our best to provide lots of opportunities for hospital staff to learn more about research and autoimmune encephalitis. We host monthly meetings where we discuss the trial and share information about autoimmune encephalitis. In the past we have helped to support clinical staff to attend the annual Encephalitis Society Conference. The trial is also part of the NIHR associate PI scheme. The Associate PI scheme gives non-research-based healthcare staff an opportunity to get involved in a large multicentre trial and helps provide a bit more support to research staff.<\/p>\n
Can you help?<\/strong><\/p>\n The condition is rare but has a severe impact on those affected. The research team is currently seeking more hospitals to join the trial. The Chief Investigator is Professor Tom Solomon<\/strong> from the University of Liverpool\u2019s Brain Infections Group.<\/p>\n If you would like to know more about the study or register as a potential site, please contact encephig@cardiff.ac.uk<\/a>or visit Enceph-IG – Centre for Trials Research – Cardiff University<\/a>. You can also follow the trial on Twitter @EncephIG<\/p>\n","protected":false},"excerpt":{"rendered":"Autoimmune encephalitis is swelling of the brain caused by the immune system attacking the body in error. It can cause people to become confused, drowsy, exhibit changes in behaviour, and […]","protected":false},"author":6918,"featured_media":2595,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[107],"tags":[],"class_list":["post-2594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-inflammation-and-immunity"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-FQ","jetpack-related-posts":[{"id":2013,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/world-encephalitis-day-enceph-ig-trial\/","url_meta":{"origin":2594,"position":0},"title":"World Encephalitis Day: Enceph-IG Trial","author":"Richard Haggerty","date":"February 22, 2021","format":false,"excerpt":"World Encephalitis Day on\u00a0February 22\u00a0is a global awareness day where individuals and families affected by encephalitis (inflammation of the brain) come together to shine a light on the condition. The Centre for Trials Research at Cardiff University is fully co-ordinating the Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults-A Randomised Double-Blind\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/02\/Enceph-IG.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":2199,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/the-nihr-associate-principal-investigator-scheme-researchers-of-the-future\/","url_meta":{"origin":2594,"position":1},"title":"The NIHR Associate Principal Investigator Scheme: Researchers of the Future","author":"Joanne Euden","date":"March 18, 2022","format":false,"excerpt":"Many of you may have heard of the Associate Principal Investigator (API) scheme, but not everyone is familiar with what it entails and how we, at the Centre for Trials Research (CTR), have involved our studies in this scheme. As more studies and trials are now registering, this blog introduces\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/03\/pexels-rodnae-productions-6129507.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2656,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/global-immune-thrombocytopenia-itp-awareness-week-2023\/","url_meta":{"origin":2594,"position":2},"title":"Global Immune Thrombocytopenia (ITP) Awareness Week 2023","author":"Joanna Smith","date":"September 21, 2023","format":false,"excerpt":"September 25-29th 2023 is Global ITP Awareness Week! This specially designated week calls for individuals around the world to join together to promote public awareness of a rare autoimmune disease called immune thrombocytopenia (ITP). The theme for this year\u2019s Global ITP Awareness Week is Increasing Awareness to Improve Outcomes and\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/Global-ITP-Awareness-Week.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2362,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/a-reflection-on-the-coverage-of-outcomes-in-the-pace-trial\/","url_meta":{"origin":2594,"position":3},"title":"A reflection On Coverage Of Outcomes In The PACE Trial Compared To COS-AECOPD","author":"David Gillespie","date":"September 27, 2022","format":false,"excerpt":"By Dr. David Gillespie and Prof. Kerenza Hood Overview In 2014, the National Institute for Health Research (NIHR) funded a randomised controlled trial (RCT) evaluating the use of a C-reactive Protein (CRP) point-of-care test (POCT) for the management of people experiencing an acute exacerbation of chronic obstructive pulmonary disease (AECOPD)\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2022\/09\/BLS8657_Print_Res-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1210,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/flight-study-milestones-researching-immune-thrombocytopenia-itp\/","url_meta":{"origin":2594,"position":4},"title":"FLIGHT Study Milestones: Researching Immune Thrombocytopenia (ITP)","author":"Julie Pell","date":"November 22, 2018","format":false,"excerpt":"FLIGHT is a\u00a0multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.\u00a0 Funded by the National Institute for Health Research (NIHR). Study background Immune Thrombocytopenia (ITP) is an illness that causes bruising and bleeding owing to a low platelet\u2026","rel":"","context":"In "Infections"","block_context":{"text":"Infections","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/infections\/"},"img":{"alt_text":"FLIGHT study is celebrating 5 milstones","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2018\/11\/FLIGHT-study-is-celebrating-5-milstones.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2668,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/raising-awareness-of-pad-pain-and-vascular-disease-the-placement-trial\/","url_meta":{"origin":2594,"position":5},"title":"Raising Awareness Of PAD, Pain And Vascular Disease: The PLACEMENT Trial","author":"Grace Young","date":"September 25, 2023","format":false,"excerpt":"This month is peripheral arterial disease (PAD) awareness month, vascular disease awareness month and pain awareness month. The number of adults with age-related chronic diseases, including PAD\/vascular disease, is increasing worldwide. Similarly, the number of adults who undergo leg amputation surgery for PAD\/vascular disease in the UK is increasing each\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/09\/PLACEMENT-Logo-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/06\/ENCEPH-IG.jpg","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/6918"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=2594"}],"version-history":[{"count":1,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2594\/revisions"}],"predecessor-version":[{"id":2596,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/2594\/revisions\/2596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media\/2595"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=2594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=2594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=2594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}